Navigation Links
New data on hormone therapy must lead to re-evaluation of official guidelines
Date:10/18/2007

As opinion leaders in the field of menopause medicine from various areas in the world, we wish to emphasize the following points concerning postmenopausal hormone therapy:

  1. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and estrogen-deficient urogenital symptoms.

  2. The initial interpretation of the Womens Health Initiative (WHI) trial failed to recognize the immense importance of age and years since menopause on outcomes of HT. The potential impact of specific hormonal regimens on safety of HT should be considered as well.

  3. The results of the WHI trial were wrongly extrapolated to the whole postmenopausal population, which led to a major change in recommendations and guidelines on HT.

  4. Based on current knowledge, the balance between the benefits and risks of HT is clearly in favor of use in the early postmenopausal years for symptomatic, healthy women.

  5. All previous studies, including the WHI trial, have demonstrated significant positive effect on bone density and reduction in fracture risk among hormone users.

  6. Estrogen has favorable metabolic and cardioprotective effects in healthy, young postmenopausal women. The results for the age group 5059 years in the WHI estrogen-alone arm support this claim. Estrogen slows the pace of development of atherosclerosis if started in the early postmenopausal period.

  7. HT may be associated with a small increase in risk for breast cancer, if taken long term. Combined estrogenprogestogen therapy probably carries a higher risk than that recorded for estrogen alone. Prevalence of stroke and thromboembolism strongly correlates with age; therefore, the impact of the HT-related increased risk in this respect becomes more important in the late menopause. Low-dose estrogen or the transdermal route of administration may lead to a more favorable risk profile.

  8. Progestins, combined with estrogen, may decrease the magnitude of estrogen-related cardiac benefits, and increase the risk for breast cancer. There are insufficient data to evaluate the possible differences in the incidence of breast cancer using different types and routes of progestin administration.

Based on the above, we call upon the health authorities to review their policies and revise them in view of the new age-related data on HT. Also, the different outcomes of estrogen-alone and estrogen plus progestin therapy should be considered. Overall, the safety profile of HT until age 60 is favorable, and should not preclude women from using HT when appropriate. Issues of quality of life, including mental, emotional, cognitive and sexual function, should have a higher priority while discussing regulatory policies and official guidelines on postmenopausal HT use.


'/>"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. Hormone replacement Therapy a headache
4. Ovarian cancer in relationship with Hormone therapy
5. Evaluating The Risks and Benefits of Hormone Therapy
6. Scientists crack mechanism of Leptin-Obesity Hormone
7. Scientists use plant hormones to fight cancer
8. Use parathyroid hormone to fight brittle bone disease
9. Multiple Sclerosis Can Be Treated By Blocking Fat Hormone
10. Hormone contraceptives lead to bone problems
11. Hormone treatment helps obese people slim down
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... America held the largest share in the ECG ... population and demand for remote monitoring ECG devices. On the ... is expected to witness the highest growth rate during the ... (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... ) and Mindray Medical International Limited ( China ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
Breaking Medicine Technology: